[go: up one dir, main page]

WO2003095484A3 - Polypeptides increasing p53 expression - Google Patents

Polypeptides increasing p53 expression Download PDF

Info

Publication number
WO2003095484A3
WO2003095484A3 PCT/GB2003/002008 GB0302008W WO03095484A3 WO 2003095484 A3 WO2003095484 A3 WO 2003095484A3 GB 0302008 W GB0302008 W GB 0302008W WO 03095484 A3 WO03095484 A3 WO 03095484A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
expression
increasing
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/002008
Other languages
French (fr)
Other versions
WO2003095484A2 (en
Inventor
Alan Fersht
Assaf Friedler
Klas G Wiman
Galina Selivanova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to AU2003230003A priority Critical patent/AU2003230003A1/en
Publication of WO2003095484A2 publication Critical patent/WO2003095484A2/en
Publication of WO2003095484A3 publication Critical patent/WO2003095484A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to polypeptides which alter the expression and/or activity of one or more tumour suppressor proteins. In particular, the present invention relates to CDB3 polypeptides which increase the expression of p53 and/or the oncogenic mutants of p53 in vivo.
PCT/GB2003/002008 2002-05-10 2003-05-09 Polypeptides increasing p53 expression Ceased WO2003095484A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003230003A AU2003230003A1 (en) 2002-05-10 2003-05-09 Polypeptides increasing p53 expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0210746.4 2002-05-10
GBGB0210746.4A GB0210746D0 (en) 2002-05-10 2002-05-10 Peptide

Publications (2)

Publication Number Publication Date
WO2003095484A2 WO2003095484A2 (en) 2003-11-20
WO2003095484A3 true WO2003095484A3 (en) 2004-01-08

Family

ID=9936436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/002008 Ceased WO2003095484A2 (en) 2002-05-10 2003-05-09 Polypeptides increasing p53 expression

Country Status (3)

Country Link
AU (1) AU2003230003A1 (en)
GB (1) GB0210746D0 (en)
WO (1) WO2003095484A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006009000B3 (en) * 2006-02-23 2007-09-06 Tutech Innovation Gmbh computational gene
CA3234720A1 (en) * 2021-10-08 2023-04-13 Sola Biosciences Llc Compositions and methods for the treatment of p53-mediated cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014144A2 (en) * 2001-08-10 2003-02-20 Medical Research Council Molecule

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014144A2 (en) * 2001-08-10 2003-02-20 Medical Research Council Molecule

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRIEDLER A ET AL.: "A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE USA, vol. 99, no. 2, 22 January 2002 (2002-01-22), pages 937 - 942, XP002257716 *
LOPEZ CHARLES D ET AL: "Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 20, no. 21, November 2000 (2000-11-01), pages 8018 - 8025, XP002189292, ISSN: 0270-7306 *

Also Published As

Publication number Publication date
AU2003230003A1 (en) 2003-11-11
WO2003095484A2 (en) 2003-11-20
GB0210746D0 (en) 2002-06-19
AU2003230003A8 (en) 2003-11-11

Similar Documents

Publication Publication Date Title
IL161016A (en) Polypeptides capable of binding to ang-2
YU9404A (en) Peptide-based multimeric targeted contrast agents
WO2006017538A3 (en) Hk1-binding proteins
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
AU2003270280A1 (en) Use of native zein for improving the condition of hair, and corresponding agent
WO2004032713A3 (en) Sealants for skin and other tissues
AU2003303458A1 (en) Ampholytic copolymer and use thereof
WO2005113592A3 (en) Interferon-alpha polypeptides and conjugates
WO2001049728A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2001023412A3 (en) Methods of screening for agents which inhibit aggregation of polypeptides
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
WO2002014499A3 (en) Claudin polypeptides
WO2004031229A3 (en) P53 binding polypeptide
WO2000029448A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
WO2007044083A3 (en) Evolved interferon-alpha polypeptides
AU2003252072A1 (en) Modulation of protein kinase c-iota expression
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2007087053A3 (en) Bmp-7 variant compositions, methods and uses
WO2003095484A3 (en) Polypeptides increasing p53 expression
WO2001088137A3 (en) Human myd88 adapter-like protein and functional fragments thereof
WO2001004297A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
WO2004089302A3 (en) Posh polypeptides, complexes and related methods
AU2003249999A1 (en) 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP